Rigorous portfolio risk analysis for drug development is not very well developed. Conventional portfolio risk assessment models do not take into consideration drugs interdependence. They also do not incorporate analysis of risk mitigation strategies. Many of them deal with operational risks, i.e. risks which could be mitigated by adding resources. At the portfolio level, analysis of strategic risk (e.g. due to a clinical trial failure) could be crucial for the company.
Join Vladimir Shnaydman for this information packed session to get a comprehensive view of methodology for portfolio risk analysis.
Here are the tools you will walk away with:
This session will cover the following topics:
Who should attend?
- Dr. Mukesh Kumar,
- Dr. David Lim, Ph.D., RAC, ASQ-CQA
- Angela Bazigos ,
- Ruchika Nijhara, PhD, MBA
- Norma Skolnik,
Vladimir Shnaydman, Ph.D, is President of ORBee Consulting. Vladimir has BS & MS Electrical Engineering & Computer Science, MS in Applied Mathematics & Operations Research, and Ph.D. in Engineering. He contributed to many industries such as biotechnology, computer networking, data storages, water resources planning and management, telecommunications, transportation, and others. Dr. Shnaydman published more than 50 papers. He is co-author of three books.